Latest Stories
ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4%
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2025, with sales up 29.6% year on year to $247.1 million. The company’s full-year revenue guidance of $1.09 billion at the midpoint came in 4.8% above analysts’ estimates. Its non-GAAP profit of $2.33 per share was 17.9% above analysts’ consensus estimates.
Carter’s (NYSE:CRI) Q4 CY2025 Sales Beat Estimates But Stock Drops
Children’s apparel manufacturer Carter’s (NYSE:CRI) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 7.6% year on year to $925.5 million. Its non-GAAP profit of $1.90 per share was 11.5% above analysts’ consensus estimates.
Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 11.5% year on year to $814.3 million. On the other hand, the company’s full-year revenue guidance of $3.1 billion at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $0.21 per share was 14.1% above analysts’ consensus estimates.
BrightSpring Health Services (NASDAQ:BTSG) Posts Better-Than-Expected Sales In Q4 CY2025
Healthcare services provider BrightSpring Health Services (NASDAQ:BTSG) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 16.3% year on year to $3.55 billion. The company’s full-year revenue guidance of $14.73 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $0.33 per share was 4.7% below analysts’ consensus estimates.
Golden Entertainment (NASDAQ:GDEN) Misses Q4 CY2025 Revenue Estimates
Casino, tavern, and slot machine operator Golden Entertainment (NASDAQ:GDEN) missed Wall Street’s revenue expectations in Q4 CY2025, with sales falling 5.2% year on year to $155.6 million. Its GAAP loss of $0.33 per share was significantly below analysts’ consensus estimates.
NVAX Q4 Deep Dive: Partnership-Led Strategy and Pipeline Transition Shape Outlook
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its non-GAAP profit of $0.11 per share was significantly above analysts’ consensus estimates.
PAYO Q4 Deep Dive: B2B Expansion and Upmarket Focus Drive Revenue, Margin Pressures Remain
Cross-border payment platform Payoneer (NASDAQ:PAYO) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 4.9% year on year to $274.7 million. The company’s full-year revenue guidance of $1.11 billion at the midpoint came in 1.6% below analysts’ estimates. Its non-GAAP profit of $0.09 per share was 37% above analysts’ consensus estimates.
Hilltop Holdings (HTH): Buy, Sell, or Hold Post Q4 Earnings?
Hilltop Holdings trades at $38.82 per share and has stayed right on track with the overall market, gaining 10.1% over the last six months. At the same time, the S&P 500 has returned 7.2%.
3 Hyped Up Stocks We’re Skeptical Of
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
3 Overrated Stocks with Warning Signs
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.